GL1X · GenesisL1 explorer

Research workbench

Crystal structures of FMS1 in complex with its inhibitors

Analyse Crystal structures of FMS1 in complex with its inhibitors in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3BI5
Type
protein
Length
996 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Polyamine oxidase FMS1
EC
1.5.3.11
UniProt
P50264
Ligands
FAD, DIA
Pockets
9 · best druggability 0.87

Structure

x-ray diffraction · 2 distinct chains · 36% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APolyamine oxidase FMS1 (EC 1.5.3.11)protein49736% helix, 21% strandP50264
BPolyamine oxidase FMS1 (EC 1.5.3.11)protein49936% helix, 19% strandP50264

Ligands and binding sites

  • FAD · Flavin-adenine dinucleotide · ligand · 2 copies · chains A, B
  • DIA · Octane 1,8-diamine · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

9 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18060.870.90102FAD, DIA
27670.870.9095FAD, DIA
31790.470.7530empty
41530.450.7519empty
51440.450.7626empty

Interfaces

1 interface between chains.

  • A–B · 1498 Ų buried · 21 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 disulfide (disulfide).

Compared structures

  • 3BI5 · Crystal structures of fms1 in complex with its inhibitors · the same entry in another collection · chain A against A, TM-score 1.00
  • P50264 · AlphaFold monomer V2.0 prediction for polyamine oxidase FMS1 (P50264) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.